Home - Products - Others - Other Targets - Competence-Stimulating Peptide-12261

Competence-Stimulating Peptide-12261

CAS No. 1235882-91-3

Competence-Stimulating Peptide-12261( —— )

Catalog No. M30330 CAS No. 1235882-91-3

Competence-Stimulating Peptide-12261, a sixteen peptide, is a fragment of competence-stimulating peptide.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    Competence-Stimulating Peptide-12261
  • Note
    Research use only, not for human use.
  • Brief Description
    Competence-Stimulating Peptide-12261, a sixteen peptide, is a fragment of competence-stimulating peptide.
  • Description
    Competence-Stimulating Peptide-12261, a sixteen peptide, is a fragment of competence-stimulating peptide.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1235882-91-3
  • Formula Weight
    2153.45
  • Molecular Formula
    C100H149N31O23
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:{Glu}{Ile}{Arg}{Gln}{Thr}{His}{Asn}{Ile}{Phe}{Phe}{Asn}{Phe}{Phe}{Lys}{Arg}{Arg}

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Jarosz LM, et al. Streptococcus mutans competence-stimulating peptide inhibits Candida albicans hypha formation. Eukaryot Cell. 2009 Nov;8(11):1658-64.
molnova catalog
related products
  • HPV-E7-N

    HPV-E7-N

  • JI130

    JI130 is able to impair the ability of Hes1 to repress transcription. JI130 treatment significantly reduced tumor volume in a murine pancreatic tumor xenograft model.

  • Zolbetuximab

    Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin-18.2-positive cells through an immune effector mechanism.